Selectively Recommend F-FDG PET/CT for Patients with De Novo Nasopharyngeal Carcinoma in Endemic Areas

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2021 Nov 28

PMID 34838075

Citations 4

Authors

Chuanben Chen

Ting Xu

Xiufang Qiu

Shihan Xie

Ziqing You

YiXin Hu

Yinghong Zheng

Zewei Liang

Chaoxiong Huang

Taojun Chen

Li Li

Jing Liu

Zhaodong Fei

Affiliations

Soon will be listed here.

Abstract

Introduction: To identify the subset of patients with de novo nasopharyngeal carcinoma (NPC) for whom [F] fluorodeoxyglucose positron emission tomography and computed tomography (F-FDG PET/CT) should be recommended, and to determine whether PET/CT is a cost-effective decision for precise M staging in endemic areas.

Materials And Methods: Retrospective analysis of data of 4469 patients diagnosed with de novo NPC between January 2014 and December 2019. The detection rate of distant metastasis was compared between different groups. Univariate and multiple logistic regression analysis was applied to identify the risk factors for distant metastasis. The cost-effectiveness of the diagnostic strategies was assessed.

Results: The detection rate of distant metastasis in the whole cohort was 5.46%. In multivariate analysis, male sex, T3-4 stage, N2-3 stage, and high plasma Epstein-Barr virus (EBV) DNA (≥ 14,650 copies/mL) were risk factors for distant metastases. NPC patients with T3-4 stage combined with N2-3 stage, high EBV DNA combined with male sex, or N2-3 stage combined with high EBV DNA were defined as recommended group with relatively higher tendency for metastasis. Distant metastasis incidence in recommended group and unrecommended group were 10.25% and 1.75%, respectively (P < 0.001). In the recommended group, PET/CT significantly improved the detection rate of distant metastasis (13.25% vs 9.02%, P = 0.005). Cost-effectiveness analysis revealed that additional cost for every one percent increase in distant metastasis detection rate was $22,785.58 in the recommended group (< Willingness-to-pay (WTP) threshold of $32,700.00) and $310,912.90 in the unrecommended group.

Conclusions: In patients with de novo NPC, the tendency for metastasis can be predicted based on clinical parameters. F-FDG PET/CT should be selectively recommended for the subset of patients with a relatively higher tendency for metastasis.

Citing Articles

Pretreatment FDG PET in prognosis of locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.

Niu X, Xue F, Ou D, Zheng Y, Hu C, Shen C Int J Med Sci. 2025; 22(4):933-939.

PMID: 39991768 PMC: 11843132. DOI: 10.7150/ijms.105995.

Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.

Fu X, Li T, Fei Z, Chen C Acta Otorhinolaryngol Ital. 2024; 44(5):296-305.

PMID: 39526766 PMC: 11556775. DOI: 10.14639/0392-100X-N2827.

Prognostic value of pre-treatment [F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis.

Dong Z, Wang G, Dai D, Qin G, Tang L, Xu C BMC Cancer. 2024; 24(1):466.

PMID: 38622555 PMC: 11017658. DOI: 10.1186/s12885-024-12189-7.

PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma.

Fei Z, Xu T, Hong H, Xu Y, Chen J, Qiu X Radiat Oncol. 2023; 18(1):33.

PMID: 36814303 PMC: 9945369. DOI: 10.1186/s13014-023-02231-6.

The Promise of Circulating Tumor DNA in Head and Neck Cancer.

Aulakh S, Silverman D, Young K, Dennis S, Birkeland A Cancers (Basel). 2022; 14(12).

PMID: 35740633 PMC: 9221491. DOI: 10.3390/cancers14122968.

References

Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J . Nasopharyngeal carcinoma. Lancet. 2019; 394(10192):64-80. DOI: 10.1016/S0140-6736(19)30956-0. View

Tang L, Chen Q, Fan W, Liu H, Zhang L, Guo L . Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial.... J Clin Oncol. 2013; 31(23):2861-9. DOI: 10.1200/JCO.2012.46.0816. View

Zhang L, Dong D, Li H, Tian J, Ouyang F, Mo X . Development and validation of a magnetic resonance imaging-based model for the prediction of distant metastasis before initial treatment of nasopharyngeal carcinoma: A retrospective cohort study. EBioMedicine. 2019; 40:327-335. PMC: 6413336. DOI: 10.1016/j.ebiom.2019.01.013. View

Ren Y, Li Y, Wu H, Wang Q, Han Y, Zhou W . Whole-body F-FDG PET/CT for M staging in the patient with newly diagnosed nasopharyngeal carcinoma: Who needs?. Eur J Radiol. 2017; 89:200-207. DOI: 10.1016/j.ejrad.2017.02.002. View

Buck A, Herrmann K, Stargardt T, Dechow T, Krause B, Schreyogg J . Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches. J Nucl Med. 2010; 51(3):401-12. DOI: 10.2967/jnumed.108.059584. View

Jerusalem G, Hustinx R, Beguin Y, Fillet G . The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol. 2002; 13 Suppl 4:227-34. DOI: 10.1093/annonc/mdf664. View

Smith S, Wachter K, Burris 3rd H, Schilsky R, George D, Peterson D . Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021; 39(10):1165-1184. DOI: 10.1200/JCO.20.03420. View

Chua M, Wee J, Hui E, Chan A . Nasopharyngeal carcinoma. Lancet. 2015; 387(10022):1012-1024. DOI: 10.1016/S0140-6736(15)00055-0. View

Chang J, Chan S, Yen T, Liao C, Lin C, Lin K . Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2005; 62(2):501-7. DOI: 10.1016/j.ijrobp.2004.09.057. View

10.

Liu F, Xiao J, Xu G, Gao L, Xu Y, Zhang Y . Fractionated stereotactic radiotherapy for 136 patients with locally residual nasopharyngeal carcinoma. Radiat Oncol. 2013; 8:157. PMC: 3702464. DOI: 10.1186/1748-717X-8-157. View

11.

Chen Z, Zhan M, Tian F, Xu T . Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma. Oncol Lett. 2020; 19(1):424-430. PMC: 6924092. DOI: 10.3892/ol.2019.11099. View

12.

Jerusalem G, Hustinx R, Beguin Y, Fillet G . PET scan imaging in oncology. Eur J Cancer. 2003; 39(11):1525-34. DOI: 10.1016/s0959-8049(03)00374-5. View

13.

Hojjat H, Svider P, Folbe A, Raza S, Carron M, Shkoukani M . Cost-effectiveness of routine computed tomography in the evaluation of idiopathic unilateral vocal fold paralysis. Laryngoscope. 2016; 127(2):440-444. DOI: 10.1002/lary.26152. View

14.

Sun X, Liang Y, Chen Q, Guo S, Liu L, Sun R . Optimizing the Treatment Pattern for Metastatic Nasopharyngeal Carcinoma Patients: A Large-Scale Retrospective Cohort Study. Front Oncol. 2020; 10:543646. PMC: 7645036. DOI: 10.3389/fonc.2020.543646. View

15.

Fei Z, Chen C, Huang Y, Qiu X, Li Y, Li L . Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma. Medicine (Baltimore). 2019; 98(28):e16327. PMC: 6641822. DOI: 10.1097/MD.0000000000016327. View

16.

Eichler H, Kong S, Gerth W, Mavros P, Jonsson B . Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health. 2004; 7(5):518-28. DOI: 10.1111/j.1524-4733.2004.75003.x. View

17.

Liu F, Chang J, Wang H, Liao C, Kang C, Ng S . [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006; 24(4):599-604. DOI: 10.1200/JCO.2005.03.8760. View

18.

You R, Liu Y, Huang P, Zou X, Sun R, He Y . Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(9):1345-1352. PMC: 7378870. DOI: 10.1001/jamaoncol.2020.1808. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Xu C, Zhang Y, Peng L, Liu X, Li W, Sun Y . Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients. J Cancer. 2017; 8(7):1238-1248. PMC: 5463439. DOI: 10.7150/jca.18361. View